Sensory neuronopathy as a major clinical feature of mitochondrial trifunctional protein deficiency in adults.
Adult
Age Factors
Cardiomyopathies
/ complications
Female
Humans
Lipid Metabolism, Inborn Errors
/ complications
Male
Middle Aged
Mitochondrial Myopathies
/ complications
Mitochondrial Trifunctional Protein
/ deficiency
Nervous System Diseases
/ complications
Peripheral Nervous System Diseases
/ diagnosis
Phenotype
Rhabdomyolysis
/ complications
Young Adult
Ganglionopathy
LCHAD deficiency
MTP deficiency
Rhabdomyolysis
Sensory neuronopathy
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
11
06
2019
revised:
22
08
2019
accepted:
07
11
2019
pubmed:
8
4
2020
medline:
3
11
2020
entrez:
8
4
2020
Statut:
ppublish
Résumé
Mitochondrial trifunctional protein deficiency (MTPD) is a long-chain fatty acid oxidation disorder characterized by co-existence of rhabdomyolysis episodes and peripheral neuropathy. Two phenotypes are described: generalized mitochondrial trifunctional protein deficiency (gMTPD) and isolated long-chain-3-hydroxyacyl-CoA dehydrogenase deficiency (iLCHADD) that is always associated with the c.1528G>C mutation. Peripheral neuropathy of MTPD is commonly described in children as axonal, length-dependent and sensorimotor. To report clinical and electrophysiological features of four independent adult MTPD patients with peripheral neuropathy. Onset of the disease was characterized in all patients by rhabdomyolysis episodes occurring during childhood preceded by severe hypoglycemic episodes in three patients. Peripheral nerve involvement manifesting as sensory ataxia appeared later, during adolescence or adulthood. In all cases, electroneuromyogram showed no length-dependent sensory potentials decrease characteristic of sensory neuronopathy ("ganglionopathy"). All patients harbored at least one c.1528G>C mutation. We describe MTPD as a newly hereditary etiology of sensory neuronopathy in adults, specifically in patients with c.1528G>C mutation. MTPD should be screened for by performing plasma acylcarnitines in patients with chronic sensory neuronopathy and additional suggestive features such as exercise intolerance or retinopathy.
Identifiants
pubmed: 32253025
pii: S0035-3787(20)30470-7
doi: 10.1016/j.neurol.2019.11.011
pii:
doi:
Substances chimiques
Mitochondrial Trifunctional Protein
EC 2.3.1.16
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-386Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.